PMID- 17618323
OWN - NLM
STAT- MEDLINE
DCOM- 20071102
LR  - 20151119
IS  - 0268-3369 (Print)
IS  - 0268-3369 (Linking)
VI  - 40
IP  - 5
DP  - 2007 Sep
TI  - Infliximab for GVHD therapy in children.
PG  - 473-80
AB  - GVHD remains a significant complication of allogeneic hematopoietic stem cell 
      transplantation. Tumor necrosis factor-alpha (TNF-alpha) is a major mediator of 
      GVHD pathogenesis. Infliximab inhibits the binding of TNF-alpha with its cellular 
      receptors and has been associated with encouraging responses in adults with 
      severe GVHD. We retrospectively evaluated the efficacy and safety of infliximab 
      10 mg/kg i.v. once a week for a median of eight doses (range 1-162) in 24 
      children with steroid-resistant GVHD. The overall response rate in 22 evaluable 
      children was 82% (12 CR+6 PR). Among those patients with acute GVHD, both skin 
      and gastrointestinal involvement responded well to infliximab; however long-term 
      outcome was poor. While infliximab may be useful to acutely control GVHD 
      manifestations, GVHD recurs commonly upon discontinuation of infliximab. Within 
      100 days of the final infliximab dose, 77% of patients had bacterial infections, 
      32% had viral infections and 13.6% had probable or proven non-candidal invasive 
      fungal infections. Infliximab appears to be well-tolerated and to have activity 
      in steroid-resistant GVHD. Controlled studies to assess the pharmacokinetics and 
      most effective dosing regimen of infliximab for the treatment of GVHD are 
      warranted.
FAU - Sleight, B S
AU  - Sleight BS
AD  - Section of Pediatric Hematology/Oncology, Department of Pediatrics, Yale 
      University, New Haven, CT, USA.
FAU - Chan, K W
AU  - Chan KW
FAU - Braun, T M
AU  - Braun TM
FAU - Serrano, A
AU  - Serrano A
FAU - Gilman, A L
AU  - Gilman AL
LA  - eng
PT  - Journal Article
DEP - 20070709
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adolescent
MH  - Anti-Inflammatory Agents/administration & dosage/adverse effects
MH  - Antibodies, Monoclonal/*administration & dosage/adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Drug Evaluation
MH  - Drug Resistance
MH  - Female
MH  - Graft vs Host Disease/complications/*drug therapy
MH  - Humans
MH  - Infant
MH  - Infliximab
MH  - Male
MH  - Opportunistic Infections/chemically induced
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2007/07/10 09:00
MHDA- 2007/11/06 09:00
CRDT- 2007/07/10 09:00
PHST- 2007/07/10 09:00 [pubmed]
PHST- 2007/11/06 09:00 [medline]
PHST- 2007/07/10 09:00 [entrez]
AID - 1705761 [pii]
AID - 10.1038/sj.bmt.1705761 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2007 Sep;40(5):473-80. doi: 10.1038/sj.bmt.1705761. Epub 
      2007 Jul 9.